Bisphosphonate use in women with breast cancer on aromatase inhibitor therapy

被引：0
|
作者：
McGowan, A. [1 ]
van der Kamp, S. [2 ]
McKenna, M. J. [1 ,2 ]
机构：
[1] St Vincents Univ Hosp, Dept Endocrinol, Dublin 4, Ireland
[2] St Vincents Univ Hosp, DXA Unit, Dublin 4, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2014年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P47
引用
收藏
页码：S463 / S463
页数：1
相关论文
共 50 条
  • [1] Prevalence of bisphosphonate therapy in women with breast cancer treated with aromatase inhibitors in Germany
    Jacob, Louis
    Kostev, Karel
    Hadji, Peyman
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (05) : 394 - 396
  • [2] Persistence to aromatase inhibitor therapy among older women with breast cancer
    Huiart, L.
    Bouhnik, A. D.
    Rey, D.
    Rousseau, F.
    Retornaz, F.
    Meresse, M.
    Bendiane, M. K.
    Viens, P.
    Giorgi, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S342 - S342
  • [3] Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
    Dieckmeyer, Michael
    Ruschke, Stefan
    Rohrmeier, Alexander
    Syvaeri, Jan
    Einspieler, Ingo
    Seifert-Klauss, Vanadin
    Schmidmayr, Monika
    Metz, Stephan
    Kirschke, Jan S.
    Rummeny, Ernst J.
    Zimmer, Claus
    Karampinos, Dimitrios C.
    Baum, Thomas
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2019, 20 (01)
  • [4] Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy
    Michael Dieckmeyer
    Stefan Ruschke
    Alexander Rohrmeier
    Jan Syväri
    Ingo Einspieler
    Vanadin Seifert-Klauss
    Monika Schmidmayr
    Stephan Metz
    Jan S. Kirschke
    Ernst J. Rummeny
    Claus Zimmer
    Dimitrios C. Karampinos
    Thomas Baum
    [J]. BMC Musculoskeletal Disorders, 20
  • [5] Safety of aromatase inhibitor therapy in breast cancer
    Lintermans, Anneleen
    Neven, Patrick
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (08) : 1201 - 1211
  • [6] Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention
    Bradford, Andrea
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (02): : 128 - 129
  • [7] The psychological consequences after adjuvant aromatase inhibitor therapy in breast cancer women
    Bianchi, E.
    Bosisio, M.
    Capri, G.
    Mariani, P.
    Miceli, R.
    Borreani, C.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Sexual Dysfunction in Postmenopausal Women with Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
    Lubian Lopez, Daniel Maria
    Butron Hinojo, Carmen Aisha
    Sanchez-Prieto, Manuel
    Mendoza, Nicolas
    Sanchez-Borrego, Rafael
    [J]. BREAST CARE, 2021, 16 (04) : 376 - 382
  • [9] Cardiovascular disease risk and statin use among women with breast cancer treated with adjuvant aromatase inhibitor therapy
    Chen, Monica F.
    Manger, Morgan
    Crew, Katherine D.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] Endocrine therapy after aromatase inhibitor therapy in breast cancer
    Verma, Mohit K.
    Miki, Yasuhiro
    Sasano, Hironobu
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (03) : 309 - 312
12345